Charles River Laboratories (CRL) Q4 2025: DSA Bookings Jump to 1.12x as Biotech Funding Rebounds
Charles River Laboratories closed 2025 with a decisive rebound in DSA bookings, fueled by a record $28 billion in biotech funding and renewed urgency from large pharma clients. Management is signaling cautious optimism for a second-half 2026 return to growth, underpinned by strategic NHP supply chain moves and disciplined cost actions. Investors should watch for margin normalization and the pace of demand conversion as the company navigates a stabilizing but still fragmented preclinical market.
Summary
- DSA Demand Turns: Improved biotech funding and pharma urgency drove a material upturn in late 2025 bookings.
- Margin Pressure Persists: Elevated NHP sourcing costs and shifting segment mix will weigh on Q1 2026 profitability.
- Strategic Realignment: Portfolio streamlining and NHP supply moves set up for margin expansion in the second half of 2026.
Performance Analysis
Charles River Laboratories ended 2025 with revenue at the upper end of guidance, but organic sales declined across all segments, reflecting a year of demand volatility. The DSA (Discovery and Safety Assessment, preclinical contract research) segment saw a 3.3% organic revenue decline in Q4, primarily due to lower discovery study volumes, though pricing and mix remained stable. RMS (Research Models and Services, animal models and related services) revenue dipped slightly in Q4, with North American small model sales still lagging pre-pandemic levels. Manufacturing Solutions also contracted, weighed down by the loss of a major cell therapy client, though microbial testing platforms performed well.
Operating margin narrowed 180 basis points in Q4 to 18.1%, pressured by lower revenue, higher NHP (non-human primate, critical research model) sourcing costs, and segment mix. Cost savings from restructuring initiatives helped cushion the impact for the full year, keeping EPS nearly flat despite the top-line decline. Notably, DSA bookings surged in Q4, with a net book-to-bill of 1.12x and backlog rising to $1.86 billion, signaling a meaningful demand inflection heading into 2026.
- DSA Bookings Acceleration: Net book-to-bill of 1.12x in Q4, up sharply from 0.82x in Q3, driven by biotech funding momentum.
- Margin Headwinds: Higher NHP sourcing costs and staffing weighed on DSA and consolidated margins in Q4 and are expected to persist into Q1 2026.
- Segment Divergence: Microbial solutions and biologics testing rebounded, while RMS and Manufacturing faced shipment timing and client-specific headwinds.
While the demand environment is stabilizing, the benefit to revenue will lag by one to two quarters due to the typical booking-to-study-start cycle. Margin normalization is expected to be back-end loaded in 2026 as NHP supply chain investments take effect.
Executive Commentary
"We are cautiously optimistic that the favorable DSA demand trends will continue in 2026 and result in a return to organic revenue growth in the second half of the year for both the DSA segment and the overall company."
Jim Foster, Chair, President, and CEO
"We expect that the DSA segment will be the primary driver of the 20 to 50 basis points of consolidated margin improvement in 2026. The margin expansion will largely be driven by the acquisition of CAF as lower sourcing costs to procure NHPs...will generate meaningful margin improvement in the second half of the year."
Birgit Gershick, Executive Vice President and COO (incoming CEO)
Strategic Positioning
1. NHP Supply Chain Control
Securing NHP sourcing is now a core lever for cost and margin control. The acquisition of KF Cambodia and Novoprim enables Charles River to internally source most of its NHP needs, reducing exposure to volatile open-market pricing. This shift is expected to drive substantial margin improvement in DSA, especially in the second half of 2026 as internal supply ramps.
2. Portfolio Streamlining and M&A Discipline
Management is actively pruning non-core assets, targeting divestitures representing 7% of 2025 revenue. Proceeds will be flexibly allocated across M&A, debt repayment, and opportunistic buybacks. Recent M&A, such as PathoQuest (in vitro quality control for biologics), aligns tightly with core scientific capabilities and offers margin accretion.
3. NAMs and AI Integration
New Approach Methodologies (NAMs, non-animal and AI-enabled testing) remain a strategic focus, but disruption risk is low in the near term. Adoption is gradual and primarily augmentative, with regulatory and data hurdles limiting immediate impact. Charles River is positioning as an enabler and validator of NAMs, not a disintermediated provider.
4. Cost Efficiency as a Strategic Imperative
Over $300 million in annualized cost savings have been executed over three years, with another $100 million targeted for 2026. These savings are critical to offsetting ongoing inflation and muted revenue growth, and are enabled by process improvement, procurement synergies, and global business services integration.
5. Geographic and Segment Expansion
China remains a growth priority, with RMS performing well and potential for broader service expansion. Biologics testing is rebounding, and microbial solutions continue to deliver stable growth, providing diversification beyond the core DSA segment.
Key Considerations
Q4 marked a turning point in demand visibility, but the path to sustainable growth remains nonlinear. Investors should track both the conversion of backlog to revenue and the normalization of margins as supply chain and cost actions take hold.
Key Considerations:
- DSA Backlog Conversion Timing: Strong Q4 bookings will not fully benefit revenue until Q2 2026 due to typical study start lags.
- Margin Improvement Levers: NHP supply chain control and ongoing cost initiatives are expected to drive margin expansion, but benefits are weighted to the second half.
- Segment-Specific Volatility: RMS faces shipment timing and cradle occupancy headwinds, while Manufacturing is recovering from client loss and regulatory delays.
- Capital Allocation Flexibility: With leverage below 3x, management retains optionality for M&A, buybacks, or debt repayment as market conditions evolve.
Risks
Near-term risks center on the pace of demand recovery and the timing of margin normalization. Prolonged biotech funding volatility, regulatory shifts in NAMs adoption, or further delays in RMS and Manufacturing recovery could pressure results. Execution risk remains on planned divestitures and the integration of new acquisitions, while the CEO transition adds an element of organizational change to monitor.
Forward Outlook
For Q1 2026, Charles River guided to:
- Flat to slightly negative reported revenue growth, with low single-digit organic decline
- Non-GAAP EPS expected to decline at a high teens rate YoY, with operating margin in the mid-teens
For full-year 2026, management maintained guidance:
- Organic revenue growth between down 1% and at least flat
- Operating margin expansion of 20 to 50 basis points
- Non-GAAP EPS of $10.70 to $11.20, up 4% to 9%
Management highlighted several factors that will shape the year:
- Margin headwinds in Q1 from NHP shipment timing and stock comp, improving in later quarters
- DSA revenue growth expected in the second half as backlog converts and NHP costs normalize
Takeaways
Charles River enters 2026 with improved demand visibility, but the recovery remains phased and margin normalization is back-end loaded.
- DSA Demand Inflection: Bookings and backlog point to a return to growth in H2 2026, but Q1 will remain soft due to study start lags and cost headwinds.
- Margin Levers in Place: NHP supply chain control and cost actions are set to drive margin expansion, but investors should expect improvement to be gradual, not immediate.
- Strategic Flexibility: Portfolio streamlining, disciplined capital allocation, and measured M&A position Charles River to capitalize as the preclinical market stabilizes.
Conclusion
Charles River Laboratories is emerging from a volatile period with clear signs of demand stabilization and a robust margin improvement roadmap. The company’s ability to convert backlog into revenue and execute on cost and supply chain levers will determine whether the second-half growth narrative materializes. Investors should monitor the pace of operational recovery and the impact of ongoing portfolio moves as the new leadership team takes the helm.
Industry Read-Through
The pronounced rebound in biotech funding and DSA bookings at Charles River signals a broader thaw in preclinical outsourcing demand, with implications for CRO peers and biopharma service providers. Persistent margin pressure from supply chain volatility and staffing costs is a cautionary signal for the sector, particularly for those with heavy exposure to NHP models or labor-intensive services. The measured pace of NAMs and AI adoption reflects the regulatory and scientific friction in replacing traditional preclinical methods, suggesting incremental rather than disruptive change for the industry. Portfolio streamlining and disciplined capital deployment are likely to remain key themes as service providers adapt to a more variable funding and demand environment.